Gritstone bio

Gritstone is developing targeted immunotherapies for cancer and infectious diseases. Gritstone's approach seeks to elicit therapeutic immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells through specific antigens. We started with a focus on tumor-specific neoantigens and have recently expanded our programs to include viral antigens displayed on the surface of virus-infected cells. The biological basis for the immune system’s recognition of abnormal cell surface targets is shared by both anti-tumor and anti-viral immunity.